Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis

OBJECTIVES: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However, the efficacy of bevacizumab in combination with erlotinib remains controversial. Therefore, we conducted a meta-analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shu, Mao, Xiao-dong, Wang, Hai-tao, Cai, Feng, Xu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932259/
https://www.ncbi.nlm.nih.gov/pubmed/27363819
http://dx.doi.org/10.1136/bmjopen-2016-011714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932259/
https://www.ncbi.nlm.nih.gov/pubmed/27363819
http://dx.doi.org/10.1136/bmjopen-2016-011714

Ejemplares similares